Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

about

Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

Item

http://www.wikidata.org/entity/Q49501136

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

@en

Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

@nl

type

Item

label

Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

@en

Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

@nl

prefLabel

Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

@en

Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

@nl

P1476

Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

@en

P2093

A Yıldırım

http://www.w3.org/2001/XMLSchema#string

A Şahin

http://www.w3.org/2001/XMLSchema#string

F M Türkcü

http://www.w3.org/2001/XMLSchema#string

H Yüksel

http://www.w3.org/2001/XMLSchema#string

M Şahin

http://www.w3.org/2001/XMLSchema#string

Z Gürsel-Özkurt

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity

On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review

Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.

Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs.

Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.

Development of refractive error in individual children with regressed retinopathy of prematurity.

Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.

Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.

Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.

P2888

s11845-017-1684-y

P31

scholarly article

P356

10.1007/S11845-017-1684-Y

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092125605

http://www.w3.org/2001/XMLSchema#string

P698

28988372

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab